Dmitry Yaranov, MD
Basic profileAdvanced Heart Failure and Transplant Cardiology
Dmitry Yaranov is a Cardiology physician. OpenAlex indexes 76 publications with 439 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6027 Walnut Grove Rd Ste 112
Memphis, TN 381202115
Telephone
901-271-1000Provider last certified this registry record 13 Feb 2024.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202583 payments$145,373openpaymentsdata.cms.gov ↗
- BridgeBio Pharma, Inc.Program year202550 payments$79,948openpaymentsdata.cms.gov ↗
- Alnylam Pharmaceuticals Inc.Program year202564 payments$74,573openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
59.6%Aldosterone antagonist (MRA)13.9%Spironolactone86%Eplerenone14%Part D<11 patientsAngiotensin receptor-neprilysin inhibitor (ARNI)12%Entresto100%Part D≥53 patients+ 12 more classes in this area
Metabolism & gastrointestinal
22.1%SGLT2 inhibitor12%Jardiance75%Farxiga25%Part D≥46 patientsGLP-1 receptor agonist4.6%Mounjaro59%Ozempic28%Wegovy13%Part D<11 patients+ 4 more classes in this area
Nervous system
10.5%Other nervous system drugs7.4%Vyndamax100%Part D≥16 patientsAntisense Oligonucleotide3.1%Wainua100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- How to build a baroreceptor activation therapy (BAT) program: from development to implementation
Journal of Cardiac Failure - Intersections
2026 - Real-World Analysis of Health Care Utilization With Baroreflex Activation Therapy for Heart Failure
Journal of Cardiac Failure
2025 - Atrial Mechanics in Heart Failure With Preserved Ejection Fraction: Effect of a No-Implant Interatrial Shunt
Circulation Heart Failure
2025 - Enteral Feeding Tube Administration of Oral Sirolimus Tablets in a Critically Ill Adult
Journal of Pharmacy Practice
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”